Nutex Health's Valuation Upgrade Reflects Strong Financial Performance and Market Position
Nutex Health, Inc. has recently experienced a significant change in its valuation grade, reflecting its strong market position. Key financial metrics include a P/E ratio of 5, a robust ROCE of 128.63%, and impressive net sales growth of 221.06%, indicating effective operational performance and financial health.
Nutex Health, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a notable shift in the company's valuation grade, which has transitioned from attractive to very attractive. Key financial metrics underscore Nutex Health's robust market position. The company boasts a P/E ratio of 5, alongside a Price to Book Value of 3.44, indicating a favorable valuation relative to its assets. Additionally, the EV to EBIT and EV to EBITDA ratios stand at 3.08 and 2.82, respectively, suggesting efficient operational performance.
Nutex Health has demonstrated strong financial health, highlighted by a remarkable ROCE of 128.63% and an ROE of 76.34%. The company has also reported impressive growth in net sales, with a year-on-year increase of 221.06%, culminating in net sales of USD 211.79 million for the latest quarter. Furthermore, the company has maintained a low Debt to EBITDA ratio of 0.16, showcasing its ability to manage debt effectively.
With high institutional holdings at 24.99%, Nutex Health continues to attract attention in the market.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
